- Press releases

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer

- Press releases

Asceneuron initiates neuroimaging trial for ASN120290

Asceneuron initiates neuroimaging trial for tau modifier ASN120290

- Event

Asceneuron panelist at BIO-Europe 2018

Asceneuron will take part to a panel discussion at BIO-Europe, on November 5th-7th, 2018 in Copenhagen, Denmark.

- Press releases

ASN120290 receives Orphan Drug Designation from the FDA

Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA

- Event

Asceneuron to present at the European Life Sciences CEO Forum

Our CEO Dirk Beher will be presenter and panellist at the 11th Annual European Life Sciences CEO Forum & Exhibition, February 26th-27th 2018, in Zurich.

- Event

Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference

Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2018 at the Westin St. Francis in San Francisco, CA.

- Event

Asceneuron to present at Neurotech Investing and Partnering Conference

Our CEO Dirk Beher will be presenter and panellist at Neurotech Investing and Partnering Conference, October 3rd 2017, in Geneva.

- News

"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring"

Read a detailed conference report on our clinical tau modifier presented at AD/PD 2017

- Press releases

Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia

- Event

Asceneuron to participate in the 1st EuroTauMeeting

Asceneuron to participate in the 1st EuroTauMeeting or how to know everything about Tau protein and associated diseases in Lille, France, on April 27-28, 2017.